Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score
Abstract
Objectives: Despite current UK guidelines recommending the use of the PSoriatic Arthritis Response Criteria (PsARC) to assess response to advanced targeted therapies in PsA patients, some clinicians use the 28-joint Disease Activity Score (DAS28), primarily developed for RA. Concordance of the two scores in PsA patients commencing advanced therapies has not previously been explored and is investigated here.
Methods: Utilising data from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS – RDN-CPMS 13910) cohort, a UK multicentre, observational study, components of PsARC and DAS28 scores were calculated at baseline (pretreatment), 3 months and 6 months following treatment, where available. DAS28-based good/moderate responses were combined and compared with PsARC responder status and agreement tested using the prevalence-adjusted bias-adjusted kappa test.
Results: Of 413 patients, 78% were classified as responders by PsARC at 3 months and 73% at 6 months and 80% by DAS28 at both 3 and 6 months. Of 218 visits, where data were recorded for patients with both PsARC and DAS28 at 3 or 6 months, 17.9% were overall discordant. Prevalence-adjusted bias-adjusted kappa values revealed ‘substantial agreement’ (64.22%) between the two scores. Further analysis between the overall concordant/discordant populations showed significant differences with PsARC patient global assessments (PtGAs), (P = 0.02).
Conclusion: PsARC and DAS28-based response criteria show ‘substantial agreement’, supporting the use of either score in patients commencing advanced therapies. PsARC PtGA was the sole significantly different (P < 0.05) subcomponent between the discordant and concordant groups, highlighting an importance in considering patient perspectives and psychosocial factors affecting response to treatment.
Related
- Adult-onset chronic nonbacterial osteitis mimicking refractory axial psoriatic arthritis: successful treatment with combined IL-1/IL-17 inhibition: a case report and brief literature review
- A Multi-Axis Plantar Load Measurement Platform for the Assessment of Foot Disorders: Comparison of Patients With Psoriatic Arthritis to a Healthy Control Cohort.
- Resolution of Nail Abnormalities in Psoriatic Arthritis
- Cutaneous Deterioration Following Glucocorticoid Discontinuation in Psoriatic Arthritis: A Real-World Cohort Study
- Sex of the Treating Rheumatologist and Disease Activity Outcomes in Psoriatic Arthritis
BibTeX
@article{patel2026measuring,
title = {{Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score}},
author = {Khadijah Patel and Moshiur Rahman Khasru and Nisha Nair and Maarten De Wit and Arnon Katz and Charlotte Thompson and Meghna Jani and Hector Chinoy and Anne Barton and Philippa Curry and James Bluett and for the OUTPASS Collaborators},
journal = {Rheumatology Advances in Practice},
year = {2026},
month = oct,
doi = {10.1093/rap/rkag120},
url = {https://doi.org/10.1093/rap/rkag120},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score
AU - Khadijah Patel
AU - Moshiur Rahman Khasru
AU - Nisha Nair
AU - Maarten De Wit
AU - Arnon Katz
AU - Charlotte Thompson
AU - Meghna Jani
AU - Hector Chinoy
AU - Anne Barton
AU - Philippa Curry
AU - James Bluett
AU - for the OUTPASS Collaborators
PY - 2026
DA - 2026/10/08
JO - Rheumatology Advances in Practice
DO - 10.1093/rap/rkag120
UR - https://doi.org/10.1093/rap/rkag120
AB - Objectives: Despite current UK guidelines recommending the use of the PSoriatic Arthritis Response Criteria (PsARC) to assess response to advanced targeted therapies in PsA patients, some clinicians use the 28-joint Disease Activity Score (DAS28), primarily developed for RA. Concordance of the two scores in PsA patients commencing advanced therapies has not previously been explored and is investigated here. Methods: Utilising data from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS – RDN-CPMS 13910) cohort, a UK multicentre, observational study, components of PsARC and DAS28 scores were calculated at baseline (pretreatment), 3 months and 6 months following treatment, where available. DAS28-based good/moderate responses were combined and compared with PsARC responder status and agreement tested using the prevalence-adjusted bias-adjusted kappa test. Results: Of 413 patients, 78% were classified as responders by PsARC at 3 months and 73% at 6 months and 80% by DAS28 at both 3 and 6 months. Of 218 visits, where data were recorded for patients with both PsARC and DAS28 at 3 or 6 months, 17.9% were overall discordant. Prevalence-adjusted bias-adjusted kappa values revealed ‘substantial agreement’ (64.22%) between the two scores. Further analysis between the overall concordant/discordant populations showed significant differences with PsARC patient global assessments (PtGAs), (P = 0.02). Conclusion: PsARC and DAS28-based response criteria show ‘substantial agreement’, supporting the use of either score in patients commencing advanced therapies. PsARC PtGA was the sole significantly different (P < 0.05) subcomponent between the discordant and concordant groups, highlighting an importance in considering patient perspectives and psychosocial factors affecting response to treatment.
SN - 2514-1775
ER -